起源、HDV基因型和持续性病毒血症决定慢性丁型肝炎患者结局和治疗应答
法国国家HDV参考中心对1112例HDV感染者进行全国回顾性研究,中位随访3.0年。出生地、HDV基因型和持续性病毒血症是肝脏受累及治疗应答的主要决定因素。非洲患者对干扰素治疗应答优于非非洲患者(46.4% vs 29.1%,p<0.001)。
要点
- 出生地、HDV基因型和持续性病毒血症是慢性HDV感染肝脏受累和治疗应答的主要决定因素。
- 欧洲HDV-1和非洲HDV-5患者发生肝硬化的风险更高。
- 持续性复制性HDV感染与失代偿、肝细胞癌和死亡相关。
核心结论
- 出生地、HDV基因型和持续性病毒血症构成慢性HDV感染患者肝脏受累和治疗应答的主要决定因素。
研究设计与样本
- 法国国家HDV参考中心开展全国性回顾性研究,纳入1112例HDV感染患者,收集从首次转诊至最后记录随访的流行病学、临床、病毒学和组学数据。
主要发现
- 队列中位年龄为36.5(29.9-43.2)岁,男性占68.6%。
- 已知出生地的患者中大多数为移民:撒哈拉以南非洲52.5%、南欧和东欧21.3%、北非和中东6.2%、亚洲5.9%、南美洲0.3%;仅150例(13.8%)为法国本土出生。
- 748例受检患者中659例(88.1%)HDV载量阳性;HDV-1占主导(75.9%),其次为撒哈拉以南基因型:HDV-5(17.6%)、HDV-7(2.9%)、HDV-6(1.8%)、HDV-8(1.6%)。
- 转诊时312例(28.2%)有肝硬化,其中一半至少经历过1次肝失代偿;无论HDV基因型如何,非洲患者肝硬化发生率显著低于欧洲患者。
- 随访结束时(中位3.0[0.8-7.2]年),48.8%的患者发生肝硬化,24.2%经历至少1次失代偿,9.2%发生肝细胞癌;欧洲HDV-1和非洲HDV-5患者发生肝硬化的风险更高;持续性复制性HDV感染与失代偿、肝细胞癌和死亡相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: HDV infection causes severe chronic liver disease in individuals infected with HBV. However, the factors associated with poor prognosis are largely unknown. Thus, we aimed to identify prognostic factors in patients with HDV infection. METHODS: The French National Reference Centre for HDV performed a nationwide retrospective study on 1,112 HDV-infected patients, collecting epidemiological, clinical, virological and histological data from the initial referral to the last recorded follow-up. RESULTS: The median age of our cohort was 36.5 (29.9-43.2) years and 68.6% of our cohort were male. Most patients whose birthplace was known were immigrants from sub-Saharan Africa (52.5%), southern and eastern Europe (21.3%), northern Africa and the Middle East (6.2%), Asia (5.9%) and South America (0.3%). Only 150 patients (13.8%) were French native. HDV load was positive in 659 of 748 tested patients (88.1%). HDV-1 was predominant (75.9%), followed by sub-Saharan genotypes: HDV-5 (17.6%), HDV-7 (2.9%), HDV-6 (1.8%) and HDV-8 (1.6%). At referral, 312 patients (28.2%) had cirrhosis, half having experienced at least 1 episode of hepatic decompensation. Cirrhosis was significantly less frequent in African than in European patients regardless of HDV genotype. At the end of follow-up (median 3.0 [0.8-7.2] years), 48.8% of the patients had developed cirrhosis, 24.2% had ≥1 episode(s) of decompensation and 9.2% had hepatocellular carcinoma. European HDV-1 and African HDV-5 patients were more at risk of developing cirrhosis. Persistent replicative HDV infection was associated with decompensation, hepatocellular carcinoma and death. African patients displayed better response to interferon therapy than non-African patients (46.4% vs. 29.1%, p <0.001). HDV viral load at baseline was significantly lower in responders than in non-responders. CONCLUSION: Place of birth, HDV genotype and persistent viremia constitute the main determinants of liver involvement and response to treatment in chronic HDV-infected patients. LAY SUMMARY: Chronic liver infection by hepatitis delta virus (HDV) is the most severe form of chronic viral hepatitis. Despite the fact that at least 15-20 million people are chronically infected by HDV worldwide, factors determining the severity of liver involvement are largely unknown. By investigating a large cohort of 1,112 HDV-infected patients followed-up in France, but coming from different areas of the world, we were able to determine that HDV genotype, place of birth (reflecting both viral and host-related factors) and persistent viremia constitute the main determinants of liver involvement and response to treatment.
引用
- Roulot D, Brichler S, Layese R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol. 2020. PMID: 32634548. doi:10.1016/j.jhep.2020.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。